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Abstract 1 
Lentiviral vectors modified from human immunodeficiency virus type 1 (HIV-1) offer a promising approach for 2 
gene therapy, facilitating transduction of genes into non-dividing cells both in vitro and in vivo. When transducing 3 
cytotoxic or anti-HIV genes, however, the vector must avoid self-inhibition by the transgene that can lead to a 4 
disruption in production of infectious virions. In this study, we constructed two HIV-1-based lentiviral vectors 5 
harboring the mifepristone-inducible gene expression unit in either the forward or reverse orientation with respect 6 
to the direction of viral genomic RNA. The ability of these vectors to transduce cytotoxic and anti-HIV genes was 7 
evaluated. When human CD14 was used as a transgene, infectious lentiviral vectors were produced by both 8 
forward and reverse vector systems. CD14 expression was efficiently induced in cells transduced by both 9 
lentiviral vectors following treatment with mifepristone. However, a higher level of basal transgene expression 10 
was observed in the forward vector system in the absence of mifepristone. In contrast, high titers of infectious 11 
lentiviral vector containing the cytotoxic vesicular stomatitis virus M gene were successfully generated using the 12 
reverse vector, but not the forward vector. In addition, when a VPS4B-dominant negative mutant against HIV-1 13 
budding was cloned into the reverse vector, significant amounts of lentiviral vector were obtained. Subsequent 14 
transduction of cells with the VPS4B mutant resulted in approximately 50% inhibition of HIV-1 production only 15 
in the presence of mifepristone. Our study thus demonstrates that incorporation of a mifepristone-regulatable 16 
gene expression unit in the reverse orientation makes significant advances towards development of a lentiviral 17 
vector that allows transduction of harmful genes. 18 
Keywords Lentiviral vector · mifepristone-regulatable system · VSV M · VPS4B 19 
20 
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Introduction 1 
A variety of gene transfer vectors based on RNA and DNA viruses have been developed to deliver foreign genes 2 
to target cells in vitro and in vivo [1]. Retroviral vectors derived from gammaretroviruses and lentiviruses have 3 
the potential advantage of sustained expression of transgenes in transduced cells because of their ability to stably 4 
integrate viral DNA into the host genome. While gammaretroviruses require cell division to establish infections, 5 
lentiviruses including human immunodeficiency virus type 1 (HIV-1) are capable of infecting both dividing and 6 
non-dividing cells [1]. Lentivirus-based vector systems thus potentiate long-term gene expression in non-dividing 7 
cells such as neurons and hematopoietic stem cells [2, 3]. 8 
Lentiviral vectors hold great promise for a gene therapy approach to inherited and acquired diseases such as 9 
cancer and acquired immunodeficiency syndrome (AIDS). A potential application of lentiviral vectors would be 10 
the transduction of a gene cytotoxic to tumor cells or virus-infected cells, resulting in the eradication of these 11 
unwanted cells from the body. For the treatment of AIDS, an alternative approach would be to deliver an 12 
anti-HIV gene to a population of cells, rendering them resistant to HIV infection. However, insertion of toxic or 13 
anti-HIV genes into an HIV-based lentiviral vector can create problems for production of the vector itself. 14 
Expression of anti-HIV transgenes in vector packaging cells can interfere with production of lentivirus particles, 15 
blocking the ability to make lentiviral vector [4]. One strategy to solve this problem is the use of a regulatable 16 
system in which the target transgene is kept silent during vector production and expression is subsequently 17 
switched on following transduction in the context of a lentiviral vector. 18 
The first generation of regulatable gene expression systems was based on naturally occurring inducible 19 
promoters [5]. However, this type of system had limitations due to high levels of “leaky” or basal expression 20 
driven by such promoters, modest induction of transgene expression, and pleiotropic activity of the inducer. For 21 
these reasons, the last two decades have seen development of chimeric regulatable systems engineered from a 22 
number of prokaryotic, eukaryotic, and viral elements designed to enhance specificity and activity of transgene 23 
expression [6]. Amongst the reported chimeric regulators is one based on a mutated human progesterone receptor 24 
which is unable to bind endogenous hormone but is activated by binding the progesterone antagonist, 25 
mifepristone (RU-486) [7, 8]. The chimeric transactivator (regulator) protein of this so-called “GeneSwitch” 26 
system comprises the GAL4 DNA-binding domain from Saccharomyces cerevisiae fused to the ligand-binding 27 
domain of a mutant progesterone receptor and the activation domain of the p65 subunit of human NF-κB [8]. In 28 
the presence of mifepristone, this transactivator binds to GAL4 activation sequences upstream of the inducible 29 
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transgene, stimulating transcription of the target gene by more than 200-fold in cultured cells [9]. An advantage 1 
of the GeneSwitch system is that the majority of its components are modified human proteins, having no impact 2 
on cell viability. In addition, although mifepristone has anti-progesterone and anti-glucocorticoid activities, the 3 
concentration needed for ligand-inducible transactivation of the target gene (10-8 to 10-11 M) is much lower than 4 
the concentration producing an anti-progesterone effect in humans [10]. Furthermore, use of a 5 
mifepristone-inducible (autoinducible) promoter to regulate expression of the chimeric transactivator 6 
dramatically reduced basal expression of the transgene in the absence of the inducer, thereby improving the 7 
dynamic range of in vivo transgene regulation [9]. 8 
Many types of regulatable gene expression systems have been incorporated into lentiviral vectors [11-21]. The 9 
most commonly used inducible system is based on the bacterial tetracycline-responsible gene expression system 10 
(Tet system) [22]. While representing an important tool for controlling target gene expression, Tet-regulatable 11 
systems in the context of lentiviral vectors have shown high basal levels of transgene expression without 12 
induction [22]. Such leakiness would be undesirable especially in the production of lentiviral vectors aimed at 13 
transducing toxic proteins into target cells.  14 
To generate a viral vector in which transgene expression was tightly controlled, we combined an HIV-1-based 15 
lentiviral vector with the GeneSwitch system described above. The mifepristone-inducible lentiviral vector 16 
reported here minimized the interference of transgene expression during virus production and permitted efficient 17 
transduction of cytotoxic and anti-HIV genes into target cells. 18 
Materials and methods 19 
Cells 20 
GeneSwitch-293 cells (a HEK293-derived human cell line expressing the GeneSwitch protein) were purchased 21 
from Invitrogen. GeneSwitch-293 and human 293T cells were maintained in Dulbecco’s modified Eagle medium 22 
(D-MEM) containing 10% fetal calf serum (FCS), 100 units/ml of penicillin, and 100 µg/ml of streptomycin 23 
(D-MEM/10% FCS). 24 
Construction of lentiviral vector plasmids 25 
The mifepristone-inducible promoter sequence, GAL4/TATA, was amplified by polymerase chain reaction (PCR) 26 
from the vector pGene/V5-His5C (Invitrogen) and subcloned into LITMUS28 (New England Biolabs) to create 27 
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pLITMUS28-GAL4/TATA. A GAL4/TATA fragment was then inserted into a Gateway-compatible lentiviral 1 
vector plasmid pYK005C [23] producing the plasmid for the forward vector (fragment positioned in the forward 2 
orientation). 3 
To generate a plasmid for the reverse vector, a fragment containing the Gateway cloning cassette, internal 4 
ribosome entry site (IRES), and humanized Renilla green fluorescent protein (hrGFP) sequences together with a 5 
fragment containing bovine growth factor hormone poly(A) (BGH pA) sequence were isolated from pYK005C 6 
and pSwitch (Invitrogen), respectively. These were subcloned into LITMUS28. Then, the GAL4/TATA sequence 7 
derived from pLITMUS28-GAL4/TATA was inserted into the subcloning plasmid. To prepare a vector backbone, 8 
the internal human elongation factor 1 α subunit promoter of a self-inactivating (SIN) lentiviral vector plasmid, 9 
CSII-EF-MCS [24], was replaced with a fragment containing GAL4/TATA, Gateway-cassette, IRES, hrGFP, and 10 
BGH pA sequences, thus generating the final plasmid. 11 
Preparation of all Gateway plasmids containing the ccdB gene was carried out using Escherichia Coli (E. 12 
Coli) strain DB3.1. 13 
Cloning of transgenes 14 
All transgenes were cloned into the lentiviral vector plasmid via the Gateway cloning system [23]. Entry plasmid 15 
clones encoding transgenes were constructed as follows. Human CD14 cDNA was amplified by PCR using 16 
primers containing the attB1 tail (5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’) at the 5’-end of the 17 
forward primer and the attB2 tail (5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-3’) at the 5’-end of the 18 
reverse primer [23]. PCR products were subcloned into the entry plasmid, pDONR201 (Invitrogen), using a 19 
Gateway BP reaction [23]. Vesicular stomatitis virus matrix protein (VSV M) cDNA fused with a FLAG epitope 20 
tag sequence (FLAG-VSV-M) was generated from a VSV M-expressing plasmid, pEGFPN3-M [25]. This 21 
involved use of a forward primer containing the attB1 tail and subsequent FLAG tag sequence 22 
(5’-ATGGATTACAAGGATGACGACGATAAG-3’) and a reverse primer containing the attB2 tail. The PCR 23 
fragment encoding FLAG-VSV-M was subcloned into entry plasmid, pDONR221 (Invitrogen) by Gateway BP 24 
reaction. Fragments encoding the VPS4B K180Q mutant (VPS4B-KQ) or firefly luciferase (Luc) were amplified 25 
by PCR from VPS4B K180Q-expressing plasmid [26] and pGL3-Basic (Promega), respectively. These fragments 26 
were inserted into EcoRI-MluI sites downstream of three FLAG epitope tags in pCMV-SPORT6-3xFLAG, a 27 
Gateway-compatible pCMV-SPORT6 (Invitrogen)-derived entry plasmid. After sequence confirmation, 28 
individual transgenes in entry plasmids were transferred to lentiviral vector plasmids by Gateway LR reaction. 29 
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Lentiviral vector production 1 
293T cells were seeded to appropriate densities 20 h prior to transfection. Infectious lentiviral vectors 2 
pseudotyped with VSV G protein were produced by lentiviral vector plasmid, VSV G- and HIV-1 Rev-expressing 3 
plasmid (pCMV-VSV-G-RSV-Rev), and HIV-1 Gag-Pol-expressing plasmid (pCAG-HIVgp) via calcium 4 
phosphate-mediated transfection, as described previously [27]. Conditioned medium was harvested 48 h 5 
post-transfection and concentrated 40-fold by ultracentrifugation at 4 °C at 100,000 x g for 90 min. 6 
For titration of the lentiviral vectors, GeneSwitch-293 cells were infected with serial dilutions of vector stocks 7 
supplemented with 10 nM mifepristone (Invitrogen) 24 h post-infection. Vector titers (transduction units: TU) 8 
were determined 48 h after induction by quantitative flow cytometric analysis for hrGFP positive cells. 9 
In the following text, the use of “p” and “v” to prefix nomenclature denotes vector plasmid and infectious 10 
lentiviral vector, respectively. 11 
Transduction and induction of transgenes 12 
GeneSwitch-293 cells were seeded in 6-well plates at a density of 1 x 105 cells/well with D-MEM/10% FCS 20 h 13 
prior to infection. Cells were then exposed to lentiviral vectors for 24 h at multiplicities of infection (MOI) of 0.1 14 
(for vF-CD14 and vR-CD14) or 5 (for vR-VSV-M). To induce transgene expression, culture medium was 15 
replaced with D-MEM/10% FCS containing 10 nM mifepristone and cells were analyzed 48 h (vF-CD14 and 16 
vR-CD14 transductions) or 24 h (for vR-VSV-M transduction) later. 17 
Flow cytometric analysis 18 
Transduced cells were incubated with anti-human CD14 mouse monoclonal antibody (61D3, eBioscience) for 20 19 
min at 4°C and then stained with Cy5-conjugated anti-mouse IgG donkey polyclonal antibody (Chemicon 20 
International Inc.) for a further 20 min at 4°C. Data were collected using the FACScalibur system (BD 21 
Bioscience) and analyzed with WinMDI software. 22 
Western blotting analysis 23 
Cells were lysed in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 5% glycerol, 0.003% bromophenol 24 
blue, 0.9% β-mercaptoethanol). Boiled samples were separated by SDS-polyacrylamide gel electrophoresis 25 
(SDS-PAGE) and transferred to Immobilion Transfer Membranes (Millipore). Primary antibodies used were: (i) 26 
anti-FLAG mouse monoclonal IgG (M2, Sigma) to detect FLAG-VSV-M; (ii) biotinylated anti-FLAG mouse 27 
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monoclonal IgG (BioM2, Sigma) to detect FLAG-VPS4B-KQ and FLAG-Luc; and (iii) anti-α-tubulin mouse 1 
monoclonal IgG (DM1A, Sigma) to detect α-tubulin. Biotinylated anti-mouse IgG (BA-2000, Vector 2 
Laboratories) was then used for the detection of FLAG-VSV-M. Proteins were detected using horseradish 3 
peroxidase (HRP)-conjugated streptavidin (ZYMED Laboratories, for FLAG-tagged proteins) and 4 
HRP-conjugated anti-mouse IgG (Cell Signalling, for α-tubulin) using a Western Lightning Chemiluminescence 5 
Reagent Plus (PerkinElmer). Signals were analyzed using a luminescence image analyzer, LAS-3000mini 6 
(Fujifilm). 7 
Microscopy analysis 8 
293T cells transfected with pF-VSV-M and pR-VSV-M were examined by light and fluorescent microscopy using 9 
an Eclipse TS100 microscope (Nikon) at the point of harvesting lentiviral vector. Images were obtained with a 10 
DFC480 digital camera and IM500 image manager software (Leica Microsystems). 11 
To detect FLAG-VSV-M, transduced cells were fixed with 4% paraformaldehyde and incubated with PBS 12 
containing 5% normal goat serum and 0.05% Triton X-100 at room temperature for 1 h. This was followed by 13 
incubation with anti-FLAG-mouse monoclonal IgG (M2) at 4°C overnight. Samples were then incubated with 14 
Alexa Fluor 594-conjugated anti-mouse IgG (Invitrogen) at room temperature for 1 h and nuclei were stained 15 
using Hoechst 33342 (Invitrogen). Images were obtained using a CTR 6500 fluorescent microscope and FW4000 16 
software (Leica Microsystems). 17 
Assay for HIV-1 release from VPS4B mutant-transduced cells 18 
GeneSwitch-293 cells were seeded at a density of 1 x 103 cells/well in a 96-well plate 20 h prior to infection and 19 
exposed to vR-VPS4B-KQ and vR-Luc at a MOI of 1 for 24 h. Transduced cells were then expanded for 4 - 5 20 
weeks and reseeded at a density of 4 x 106 cells in a 15 cm diameter dish 20 h prior to induction. A portion of 21 
transduced cells was subjected to flow cytometric analysis to monitor hrGFP expression after induction with 10 22 
nM mifepristone. To enrich transduced cells, single hrGFP positive cells were positively selected using the 23 
FACSAria cell sorting system (BD Bioscience). Sorted cells were cultured for a further 4 - 5 weeks and cell 24 
clones with the strongest hrGFP signals in respective transductions were used for an assay of HIV-1 release. 25 
For the assay of HIV-1 release, 4 µg of pNL4-3 [28] was transfected to transduced cells with Lipofectamine 26 
2000 (Invitrogen). Four hours post-transfection, culture medium was replaced with D-MEM/10% FCS containing 27 
10 nM mifepristone. Culture supernatant was harvested 24 h later and virus production was monitored by HIV-1 28 
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p24CA enzyme-linked immunosorbent assay (ELISA, ZeptoMetrix). 1 
Statistical analysis 2 
Student’s t test was used to determine statistical significance. A P value of <0.05 was considered significant. 3 
Results 4 
Generation of mifepristone-inducible lentiviral vectors 5 
In order to establish a regulatable viral vector system, we cloned a mifepristone-inducible promoter sequence (as 6 
an internal promoter) into a self-inactivating (SIN) lentiviral vector plasmid in which the U3 region of the 5’ long 7 
terminal repeat (LTR) was replaced with the cytomegalovirus (CMV) promoter and the enhancer/promoter unit 8 
was deleted from the U3 region of the 3’ LTR [23, 27]. The inducible promoter was a hybrid consisting of the 9 
yeast GAL4 upstream activating sequences linked to the adenovirus major late E1b TATA box (GAL4/TATA) [7]. 10 
Gene expression from the GAL4/TATA promoter was controlled by a chimeric regulatory protein termed 11 
GeneSwitch. Binding of mifepristone to GeneSwitch induced a conformational change in the regulator to an 12 
active state, resulting in transcription of the gene of interest [7]. Besides an inducible promoter, our lentiviral 13 
vectors contained a Gateway cloning system reading frame cassette, facilitating cloning of genes of interest by 14 
site-specific recombination-based Gateway technology [23]. In addition to a conventional lentiviral vector 15 
containing the GAL4/TATA-Gateway component in the forward orientation (forward vector, Fig. 1a), we also 16 
constructed a version of the lentiviral vector plasmid in which the inducible gene expression unit was located in 17 
the reverse orientation, with the intention of reducing interference from the CMV promoter (reverse vector, Fig. 18 
1a). 19 
To evaluate our gene delivery system, the human CD14 gene was cloned into both forward and reverse vector 20 
plasmids (designated pF-CD14 and pR-CD14, respectively). Infectious lentiviral vectors (vF-CD14 and 21 
vR-CD14) were produced following co-transfection of VSV G/Rev-expressing plasmid and Gag-Pol-expressing 22 
plasmid into 293T cells. Flow cytometric analysis of transfected cells showed that even in the absence of the 23 
GeneSwitch protein and mifepristone, expression of CD14 and cistronic hrGFP genes occurred in 24 
pF-CD14-transfected producer cells (40.7 ± 3.1 %), while such expression was repressed in pR-CD14-transfected 25 
cells (1.4 ± 0.4 %) (Fig. 1b). This leaky expression of transgenes from the forward vector plasmid in virus 26 
producer cells might be due to transcriptional interference arising from the presence of a heterologous promoter 27 
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in the same orientation (i.e. the CMV promoter), which was required for Tat-independent transcription of the viral 1 
RNA genome [27]. Culture supernatant containing the lentiviral vector was harvested and viral titer determined 2 
by quantification of the number of hrGFP-positive cells in viral vector-transduced GeneSwitch-293 cells, 3 
expressing the GeneSwitch regulatory protein, in the presence of mifepristone [8]. Lentiviral vectors produced by 4 
pF-CD14 showed 34.4-fold higher viral titers (vF-CD14, 2.0 ± 0.5 x 106 TU/ml) than viral vectors obtained by 5 
pR-CD14 (vR-CD14, 5.8 ± 1.1 x 104 TU/ml) (Fig. 1c). The transduction and induction efficiencies of lentiviral 6 
vectors were then assessed following infection of GeneSwitch-293 cells at a MOI of 0.1. As shown in Fig. 1d, a 7 
low level of CD14 expression in transduced cells was observed in both vF-CD14- and vR-CD14-infected cells in 8 
the absence of mifepristone. However, basal gene expression in vF-CD14-infected cells (16.5 ± 1.7%) was higher 9 
than that recorded in vR-CD14-infected cells (6.3 ± 2.2%), indicating that transgene expression from the reverse 10 
orientation vector was tightly controlled in both transduced cells and virus producer cells (Fig. 1b and d). In the 11 
presence of mifepristone, expression of CD14 increased significantly, with the percentage of CD14-positive cells 12 
rising to 78.6 ± 0.6% (vF-CD14) and 44.3 ± 9.9% (vR-CD14) (Fig. 1d). The regulation factor (ratio of maximal 13 
induced expression to basal expression levels in the absence of the inducer [29]), of vR-CD14 was higher than 14 
that of vF-CD14 (7.0-fold versus 4.7-fold). These results demonstrated that our mifepristone-inducible lentiviral 15 
vectors functioned as an efficient gene delivery system with a tight on-off switch for regulating transgene 16 
expression. 17 
Transduction of a cytotoxic gene by the mifepristone-inducible lentiviral vector 18 
In gene therapies for cancer patients, delivery of a cytotoxic gene by lentiviral vector is one strategy for 19 
destroying tumor cells. However, expression of a toxic gene in a lentiviral vector genome would hamper vector 20 
production, resulting in a reduction in titer. Expression of such a cytotoxic gene thus needs to be blocked during 21 
the process of vector production. The lentiviral vector described here, containing a mifepristone-inducible gene 22 
expression unit in the reverse orientation, shows great promise as a carrier for a cytotoxic transgene with CD14 23 
expression tightly repressed in pR-CD14-transfected producer cells (Fig. 1b). We examined this system further to 24 
ascertain if it could produce infectious lentiviral vector containing a cytotoxic gene and transduce that gene into 25 
target cells. Forward and reverse vector plasmids containing FLAG tag-fused VSV matrix protein 26 
(FLAG-VSV-M) were constructed (pF-VSV-M and pR-VSV-M, Fig. 2a) and transfected into 293T cells to 27 
produce VSV G-pseudotyped infectious vector. VSV M was chosen as it inhibits nuclear export of cellular RNA 28 
by interacting with nucleoporin. This protein is responsible for most of the cytopathic effects observed in 29 
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VSV-infected cells [30]. Analysis of the level of FLAG-VSV-M in virus producer cells showed that, even in the 1 
absence of inducers, transgene expression was activated in pF-VSV-M-transfected cells, while expression was 2 
undetectable in pR-VSV-M-transfected cells (Fig. 2b). As predicted by western blotting analysis, activated 3 
expression of the downstream hrGFP cistron, together with the rounded phenotype of infected cells (a hallmark 4 
of VSV infection in cell culture [30]), was observed in pF-VSV-M-transfected cells (Fig. 2c). In contrast, 5 
pR-VSV-M-transfected cells exhibited neither hrGFP expression nor cytopathic effect, demonstrating the ability 6 
of the reverse vector to suppress the cytotoxic gene in virus producer cells (Fig. 2c). Importantly, the ability of 7 
pR-VSV-M to suppress VSV M expression was reflected in the production of infectious lentiviral vector from 8 
transfected cells. Transfection with pR-VSV-M yielded lentiviral vector (vR-VSV-M) with titers of 1.5 ± 0.5 x 9 
104 TU/ml while no infectious vector could be obtained by transfection with pF-VSV-M (Fig. 2d). The ability of 10 
vR-VSV-M to transduce the transgene was then analyzed by infection of GeneSwitch-293 cells. Immunostaining 11 
analysis indicated that FLAG-VSV-M expression was induced in response to mifepristone in transduced cells 12 
(Fig. 2e) and the regulation factor (i.e. inducibility) was 11.8-fold (FLAG positive cells per Hoechst 33342 13 
positive cells, 4.6 ± 3.2% without mifepristone treatment versus 54.5 ± 20.6% with mifepristone treatment, Fig. 14 
2f). These data demonstrated that our reverse vector system is suitable for the transduction of a harmful gene. 15 
Inhibition of HIV-1 release by mifepristone-inducible lentiviral vector 16 
To evaluate whether the reverse vector could overcome self-inhibition caused by an anti-HIV transgene in 17 
producer cells, a dominant negative mutant of human VPS4B was selected as a transgene. VPS4B is one of two 18 
known isoforms of AAA-ATPase VPS4 and is thought to catalytically remove ESCRT (endosomal sorting 19 
complex required for transport) complex III proteins from the plasma membrane, resulting in budding of HIV-1 20 
from infected cells [26]. The ATPase activity of VPS4B is essential for HIV-1 budding, with dominant negative 21 
mutants of VPS4 (such as K180Q, where the residues required for ATP binding have been mutated) previously 22 
reported to block HIV-1 release and infectivity [26]. We inserted a FLAG tag-fused VPS4B K180Q mutant 23 
(FLAG-VPS4B-KQ) into both the forward and reverse vector plasmids and constructed vector plasmids encoding 24 
FLAG tag-fused luciferase (FLAG-Luc) as control vectors (Fig. 3a). When these vector plasmids were used to 25 
produce lentiviral vector, expression of the transgenes (i.e. FLAG-VPS4B-KQ or FLAG-Luc) was observed in 26 
producer cells transfected with forward vector plasmids, but not in cells with reverse vector plasmids (Fig. 3b). 27 
While transfection with pR-VPS4B-KQ yielded infectious lentiviral vector, vR-VPS4B-KQ, transfection with 28 
pF-VPS4B-KQ did not generate infectious vector, indicating that leaky expression of the VPS4 dominant 29 
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negative mutant from the forward vector plasmid self-inhibited lentiviral vector production (Fig. 3c). Titers of 1 
vR-VPS4B-KQ (8.7 ± 2.4 x 104 TU/ml) were comparable to those of lentiviral vector obtained by transfection 2 
with pR-Luc (vR-Luc, 5.9 ± 4.1 x 104 TU/ml), indicating that titers of lentiviral vectors containing the gene 3 
expression unit in a reverse orientation were not affected by the anti-HIV transgene (Fig. 3c). 4 
The ability of our lentiviral vectors to transduce the VPS4B dominant negative mutant for inhibition of HIV-1 5 
release was then tested. GeneSwitch-293 cells were infected with vR-VPS4B-KQ and vR-Luc and sorted for 6 
hrGFP positive cells. When transduced cells were cultured with mifepristone, induction of transgene expression 7 
was seen (Fig. 3d). The inhibitory effect of transgenes on HIV-1 release from transduced cells was examined by 8 
transiently transfecting a plasmid DNA producing infectious HIV-1 virions (pNL4-3). In the presence of 9 
mifepristone, levels of HIV-1 production from vR-VPS4B-KQ-transduced cells dropped to 53.9 ± 8.5%, 10 
approximately half that seen in the absence of mifepristone treatment. However, no significant inhibitory effects 11 
on HIV-1 release were observed in vR-Luc or mock-transduced cells (112.3 ± 9.0% and 89.7 ± 3.1%, 12 
respectively). This indicated that induced expression of dominant negative mutant VPS4B proteins in transduced 13 
cells accounted for the observed inhibition of HIV-1 release. These results demonstrate the utility of our reverse 14 
vector to transduce an anti-HIV gene that functionally suppresses HIV-1 release in target cells. 15 
Discussion 16 
The basic principle of current gene therapy is to deliver genetic material to a population of cells in the body, 17 
thereby preventing a disease or improving the clinical status of a patient. Although a key factor in successfully 18 
implementing gene therapy is the development of effective vector systems, a number of issues need to be 19 
addressed to apply them in a clinical setting. In terms of viral vector systems, one of the major problems is that 20 
insertion of cytotoxic or antiviral transgenes adversely affects viral titers during vector production. In this study, 21 
we incorporated a mifepristone-inducible gene expression unit into HIV-1-based lentiviral vectors to solve the 22 
problem of vector self-inhibition. 23 
Previous studies have reported the delivery of various anti-HIV genes by HIV-1-based vectors in vitro and in 24 
vivo [31-36]. Some of the transgenes used in these studies target HIV-1 RNA sequences either directly or 25 
indirectly, aiming to inhibit transcription, nuclear translocation, or translation of viral RNA [32-36]. In these 26 
types of approach, the problem of self-inhibition can be solved by modifying the nucleotide sequence of a 27 
lentiviral vector such that the function of the vector RNA does not interfere with the anti-HIV transgene in 28 
producer cells. However, if the transgene targets a fundamental process of the HIV-1 life cycle, such as virion 29 
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formation, another strategy to avoid self-inhibition is to express the transgene in a regulated manner such that its 1 
expression is blocked in producer cells and induced in target cells. This kind of approach would be of value in the 2 
transduction of a harmful gene into target cells. The data presented here demonstrate that a lentiviral vector 3 
bearing a regulatable gene expression unit is indeed capable of transducing cytotoxic (VSV M) and anti-HIV 4 
(VPS4B K180Q) genes into target cells without significant decrease in vector titer (Fig. 2 and 3). In addition, 5 
induction of anti-HIV genes in transduced cells resulted in approximately 50 % inhibition of HIV-1 release (Fig. 6 
3e). 7 
Expression of VPS4B-KQ mutant by transfection has been reported to inhibit HIV-1 release >100-fold [26], 8 
although the VPS4B-KQ expression induced by our mifepristone-regulatable system produced about 2-fold 9 
reduction in HIV-1 production (Fig. 3e). When we looked at the IRES-controlled hrGFP expression in 10 
mifeprisone-induced cells that had been transduced by vR-VPS4B-KQ or vR-Luc and sorted, hrGFP expressions 11 
were only observed in 10.5% (vR-VPS4B-KQ) or 12.2% (vR-Luc) of the cells (data not shown). We speculate 12 
that uninducible population of cells was still permissive to HIV-1 production and thus lead to the observed 50% 13 
inhibition in the vR-VPS4B-KQ-transduced cells. During expansion of these tranduced cells after cell sorting it is 14 
possible that some (e.g. gene shut-off) lost their ability to be induced by mifopristone. Besides, the cell sorting 15 
step might lead to this issue of lost inducibility. Therefore improving the way to enrich transduced cells should 16 
help to alleviate this problem. 17 
To achieve tight regulation of transgene expression, enabling production of infectious vectors, it was 18 
necessary to place the mifepristone-inducible gene expression unit in the reverse orientation in the context of the 19 
lentiviral vector. Sirin and Park [12] tested the forward and reverse orientations of a mifepristone-inducible gene 20 
expression unit in HIV-1-based lentiviral vectors and reported basal levels of transgene expression that were 21 
higher in lentiviral vectors bearing the expression cassette in the reverse orientation than those containing it in the 22 
forward orientation. This was in contrast to the findings presented here, where basal expression of the CD14 23 
transgene in reverse vector-infected cells appeared to be lower than that in forward vector-infected cells (Fig. 1d). 24 
Similarly to the Sirin and Park [12] study, we used an HIV-1-based SIN vector in which the woodchuck 25 
post-regulatory element (WPRE) was inserted into the 3’ untranslated region of the viral genome (Fig. 1a). 26 
WPRE has been reported to increase the stability of RNA transcripts, thereby enhancing transgene expression 27 
from retroviral and lentiviral vectors [37]. Interestingly, WPRE functions only when placed in the sense 28 
orientation of a transgene and antisense WPRE actually shows an inhibitory effect on transgene expression [37]. 29 
In our reverse vector, WPRE was positioned in the opposite orientation to the inducible gene expression unit (Fig. 30 
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1a), while the vector designed by Sirin and Park contained WPRE in same orientation as the expression unit [12]. 1 
Orientation-dependent elements such as WPRE can thus enhance basal expression of a transgene in both 2 
producer and transduced cells. In addition to WPRE, the SIN vector used in our study contained a hybrid 5’ LTR 3 
in which the U3 region was replaced with the CMV promoter [27]. We speculate that, in the context of our 4 
forward vector, these cis-acting sequences should increase background activity of the mifepristone-regulatable 5 
gene expression unit without induction, leading to leaky expression of cytotoxic/anti-HIV genes in producer cells 6 
and significant loss of vector titers (Fig. 2d and 3c). 7 
One general drawback of regulatable gene expression systems, including the Tet and mifepristone systems, is 8 
that they necessitate delivery of two expression units into a target cell; one to express the transactivator and the 9 
other to express the transgene in response to the activator. To exclude differences in experimental conditions due 10 
to differing levels of transactivator expression, a cell line stably expressing the GeneSwitch transactivator was 11 
used as a target cell in this study. While Sirin and Park also described a two-lentiviral vector system in which 12 
GeneSwitch and inducible gene expression units were cloned into separate vectors [12], this type of binary 13 
approach would produce populations of singly transduced cells with either transactivator or transgene, resulting 14 
in low inducibility. Single-lentiviral vectors bearing the entire regulatable unit have been developed in Tet 15 
systems [11, 38, 39]. This single-vector approach would be an attractive option for the mifepristone-regulatable 16 
system, bypassing the need for co-transduction of target cells with high amounts of virus. However, RNA 17 
virus-based vectors, such as lentiviral vectors, are limited in their cloning capacity for larger genes. Theoretically, 18 
lentiviral vectors can accommodate 7 – 7.5 kb of foreign DNA [1], yet this packaging capacity will be decreased 19 
by the insertion of additional regulatory sequences. Improvements to the mifepristone system that would allow 20 
incorporation of both transactivator and inducible units into a single-lentiviral vector would be necessary to 21 
design a more versatile vector. 22 
The mifepristone-regulatable gene expression system reported here has a number of potential advantages that 23 
suit it to gene therapy applications in humans. Firstly, the majority of the system consists of modified human 24 
proteins with no impact on cell viability. Secondly, the induction response is specific and rapid. Thirdly, 25 
mifepristone is orally effective and the dose required for induction is within the range acceptable for clinical use 26 
[10]. Importantly, mifepristone has been approved by the Food and Drug Administration (FDA) for use in 27 
humans. Although no gene regulatory system has yet been approved by the FDA for clinical use, lentiviral 28 
vectors in conjunction with a mifepristone-regulatable gene expression system are a promising step towards 29 
achieving successful gene therapy. 30 
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Figure legends 1 
Fig. 1 Transduction of the CD14 gene by mifepristone-inducible lentiviral vectors. a Schematic of forward and 2 
reverse vectors. In these SIN lentiviral vector plasmids, the U3 region of the 5’ LTR has been replaced with the 3 
CMV promoter (CMVP) resulting in Tat-independent transcription. A portion of the U3 region containing the 4 
enhancer/promoter unit has been deleted from the 3’ LTR (represented as triangles). The gene of interest 5 
(transgene), flanked by attB sites, was subcloned into an entry plasmid and then transferred to the vector plasmid 6 
by a Gateway reaction. Note that site-specific recombination between attR sites on the vector plasmid and attL 7 
sites on the entry vector gave rise to new attB sites on the final lentiviral vector plasmid. The GAL4/TATA 8 
promoter regulated expression of the transgene and IRES-controlled hrGFP gene in the presence of the 9 
transactivator protein (GeneSwitch) and mifepristone. Ψ, packaging signal; RRE, Rev responsive element; 10 
WPRE, woodchuck post-regulatory element; BGH pA, bovine growth factor hormone poly(A). b Expression of 11 
CD14 in vector producer cells. 293T cells were co-transfected with a VSV G/Rev-expressing plasmid, a 12 
Gag-Pol-expressing plasmid, and a forward or reverse vector plasmid coding CD14 and hrGFP genes (pF-CD14 13 
and pR-CD14, respectively). Expression of CD14 (y-axis) and hrGFP (x-axis) at the time of vector harvest (48 h 14 
after transfection) was analyzed by flow cytometric analysis. Untransfected cells (mock) served as a negative 15 
control. The representative results of three independent experiments are shown. c Infectious titers of lentiviral 16 
vectors. Vector titer (transducing units [TU]/ml) was determined by quantitative flow cytometric analysis for 17 
hrGFP positive cells on transduced GeneSwitch-293 cells in the presence of mifepristone. Values represent the 18 
mean ± standard deviation (SD) for triplicate determinations. d Transduction and induction activities of lentiviral 19 
vectors. GeneSwitch-293 cells were infected with vF-CD14 or R-CD14 at a MOI of 0.1 (or uninfected, mock) 20 
and cultivated in the presence or absence of 10 nM mifepristone (Mif (+) and Mif (-), respectively). Expression 21 
of CD14 protein 48 h after induction was determined by flow cytometric analysis. Values represent the mean ± 22 
SD of three independent experiments. The P value versus no mifepristone treatment is <0.05 by Student’s t test 23 
(*) 24 
Fig. 2 Effective transduction of VSV M by the reverse vector. a Forward and reverse vectors containing 25 
FLAG-tagged VSV M (FLAG-VSV-M) as a transgene (pF-VSV-M and pR-VSV-M, respectively). b Expression 26 
of FLAG-VSV-M in vector producer cells. 293T cells were co-transfected with a VSV G/Rev-expressing plasmid, 27 
a packaging plasmid, and pF-VSV-M or pR-VSV-M to produce lentiviral vectors. Cell extracts were prepared 48 28 
h after transfection and subjected to western blotting (WB) analysis using anti-FLAG (upper panel) and 29 
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anti-α-tubulin (lower panel) antibodies. c Leaky expression of VSV M caused the death of producer cells. 1 
Fluorescent (upper panels) and light (lower panels) microscopic analysis of producer cells was undertaken at the 2 
time of vector harvest. Scale bar, 40 µm. d Titers of lentiviral vectors bearing the VSV M gene. TU was 3 
determined by hrGFP positive cells in GeneSwitch-293 cells in the presence of mifepristone. The expression of 4 
hrGFP in vF-VSV-M-infected cells was below the detection limit (not detected, N.D.). Value of vR-VSV-M 5 
represents the mean ± SD of three independent experiments. e Inducible expression of FLAG-VSV-M in 6 
vR-VSV-M-transduced cells. GeneSwitch-293 cells were infected with vR-VSV-M at a MOI of 5 and fixed with 7 
paraformaldehyde 24 h after induction. Expression of FLAG-VSV-M was examined as described in materials and 8 
methods. Hoechst 33342 indicates nucleus. Mif (-), without mifepristone treatment; Mif (+), with 10 nM 9 
mifepristone treatment; scale bar, 100 µm. f Quantification of inducibility. FLAG-VSV-M positive cells observed 10 
by immunofluorescence analysis were counted in a randomly selected visual field. Data are expressed as the 11 
percentage of FLAG+ cells in Hoechst 33342+ cells (mean ± SD of four independent transductions). The P value 12 
versus no mifepristone treatment is <0.05 by Student’s t test (*) 13 
Fig. 3. Inhibition of HIV-1 release by a reverse vector encoding VPS4B dominant negative mutant. a Schematic 14 
representation of forward and reverse vectors bearing FLAG-tagged VPS4B K180Q (FLAG-VPS4B-KQ) or 15 
luciferase (FLAG-Luc). b Expression of transgenes in vector producer cells. The lentiviral vectors were produced 16 
as described in materials and methods. Producer cells were collected at the time of virus harvest and subjected to 17 
western blotting (WB) analysis using anti-FLAG (upper panels) and anti-α-tubulin (lower panels) antibodies. c 18 
Titers of lentiviral vectors. N.D. means below the detection limit of flow cytometric analysis for hrGFP 19 
expression. d Induction of FLAG-VPS4B-KQ and FLAG-Luc expressions by reverse vectors. GeneSwitch-293 20 
cells were infected with vR-VPS4B-KQ or vR-Luc at a MOI of 1 and cultivated in the absence of mifepristone. 21 
After sorting of cell clones that were capable of expressing hrGFP, the inducibility of FLAG-VPS4B-KQ and 22 
FLAG-luciferase expression was analyzed by western blotting. Mif (-) and Mif (+) indicate before and after 23 
induction with mifepristone, respectively. e Analysis of HIV-1 production in transduced cells. GeneSwitch-293 24 
cell lines transduced with either vR-VPS4B-KQ or vR-Luc (and untransduced cells, mock) were transiently 25 
transfected with pNL4-3. The amount of HIV-1 virions present in the culture supernatant was measured by p24CA 26 
ELISA. The efficiency of HIV-1 release in the presence of 10 nM mifepristone is shown as a percentage of the 27 
value in the absence of mifepristone (mean ± SD of three independent transfections). The P value versus no 28 
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Fig. 3c-e (Shinoda et al.
